Literature DB >> 19740405

Phenytoin-induced reduction of voriconazole serum concentration is not compensated by doubling the dosage.

Jan-Willem C Alffenaar, Kim C M van der Elst, Donald R A Uges, Jos G W Kosterink, Simon M G J Daenen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19740405      PMCID： PMC2766487          DOI： 10.1111/j.1365-2125.2009.03464.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  9 in total

1.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.

Authors:  Thomas J Walsh; Elias J Anaissie; David W Denning; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; Brahm H Segal; William J Steinbach; David A Stevens; Jo-Anne van Burik; John R Wingard; Thomas F Patterson
Journal:  Clin Infect Dis       Date:  2008-02-01       Impact factor: 9.079

2.  CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole.

Authors:  Johanna Weiss; Magdalena Maria Ten Hoevel; Jürgen Burhenne; Ingeborg Walter-Sack; Michael Marcus Hoffmann; Jens Rengelshausen; Walter E Haefeli; Gerd Mikus
Journal:  J Clin Pharmacol       Date:  2008-11-25       Impact factor: 3.126

3.  High voriconazole trough levels in relation to hepatic function: how to adjust the dosage?

Authors:  Jan-Willem C Alffenaar; Tessa de Vos; Donald R A Uges; Simon M G J Daenen
Journal:  Br J Clin Pharmacol       Date:  2008-12-16       Impact factor: 4.335

4.  The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers.

Authors:  Guo Wang; He-Ping Lei; Zhi Li; Zhi-Rong Tan; Dong Guo; Lan Fan; Yao Chen; Dong-Li Hu; Dan Wang; Hong-Hao Zhou
Journal:  Eur J Clin Pharmacol       Date:  2008-11-04       Impact factor: 2.953

Review 5.  Drug interactions between chemotherapeutic regimens and antiepileptics.

Authors:  Kevin Yi-Lwern Yap; Wai Keung Chui; Alexandre Chan
Journal:  Clin Ther       Date:  2008-08       Impact factor: 3.393

6.  Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients.

Authors:  Steve Trifilio; Gennethel Pennick; Judy Pi; Jennifer Zook; Mary Golf; Kimberley Kaniecki; Seema Singhal; Stephanie Williams; Jane Winter; Martin Tallman; Leo Gordon; Olga Frankfurt; Andrew Evens; Jayesh Mehta
Journal:  Cancer       Date:  2007-04-15       Impact factor: 6.860

7.  Breakthrough Candida infections in patients receiving voriconazole.

Authors:  Lana Gerzenshtein; Shilpa M Patel; Kimberly K Scarsi; Michael J Postelnick; John P Flaherty
Journal:  Ann Pharmacother       Date:  2005-05-24       Impact factor: 3.154

8.  Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration.

Authors:  Lynn Purkins; Nolan Wood; Parviz Ghahramani; Edward R Love; Malcolm D Eve; Anitra Fielding
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

Review 9.  Optimal prevention of seizures induced by high-dose busulfan.

Authors:  Andrea L Eberly; Gail D Anderson; Joseph S Bubalo; Jeannine S McCune
Journal:  Pharmacotherapy       Date:  2008-12       Impact factor: 4.705
  9 in total
  2 in total

1.  Increasing the dose of voriconazole compensates for enzyme induction by phenytoin.

Authors:  Isabel Spriet; Philippe Meersseman; Wouter Meersseman; Jan de Hoon; Ludo Willems
Journal:  Br J Clin Pharmacol       Date:  2010-06       Impact factor: 4.335

2.  Determination of a suitable voriconazole pharmacokinetic model for personalised dosing.

Authors:  David A J McDougall; Jennifer Martin; E Geoffrey Playford; Bruce Green
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-12-16       Impact factor: 2.745
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.